Information Provided By:
Fly News Breaks for May 23, 2019
ACOR
May 23, 2019 | 06:43 EDT
As previously reported, Wedbush analyst Laura Chico started Acorda Therapeutics with a Neutral rating and $12 price target. The analyst notes that the loss of exclusivity for the company's flagship Ampyra product has led to Inbrija - its inhaled levodopa product for the treatment of OFF episodes in Parkinson's disease - to the forefront of its lineup. Chico states that while her recent survey suggests that physicians will continue to increase their Inbrija utilization, it is unclear how many patients may be "appropriate candidates for the drug," and with only 2 months on the market, additional feedback is needed on its potential expected demand.
News For ACOR From the Last 2 Days
There are no results for your query ACOR